Alembic Pharmaceuticals gets USFDA's tentative approval for type 2 diabetes drug

The tentatively approved abbreviated new drug application (ANDA) is therapeutically equivalent to the reference listed drug product Glyxambi tablets, 10 mg/5 mg and 25 mg/5 mg, of Boehringer Ingelheim Pharmaceuticals, Inc.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2EDJwLY
via IFTTT